Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Telotristat Etiprate in Renal Impairment
NCT03442725Phase 1Completed
- Sponsor
- Ipsen
- Start
- Feb 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of telotristat ethyl in Carcinoid Syndrome (CS) (4 arms), sponsored by Ipsen. Primary endpoints: Maximum Plasma Concentration at Day 4, Time to Maximum Observed Plasma Concentration at Day 4 and 6 more. Started Feb 2018; status: completed.
02
Drugs
telotristat ethyl
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NCT03442725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03442725.